17 Aug 2023 , 11:54 AM
Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received final approval from the USFDA for generic Icatibant injection used in treating hereditary angioedema. The approved injection is of strength 30 mg/3 mL (10 mg/mL) and comes in a single-dose pre-filled syringe.
The product is considered bioequivalent and therapeutically equivalent to Takeda Pharmaceuticals’ reference listed drug FIRAZYR. Aurobindo Pharma announced the product’s launch in September 2023. The approved product’s market size is estimated to be approximately USD 137 million based on IQVIA data for the 12 months ending June 2023.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
